Otelixizumab  (Synonyms: ChAglyCD3; TRX 4)

Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes^[1].

Human IgG1 lambda2

Human IgG1 lambda2, Isotype Control

Human

CD3

Otelixizumab (ChAglyCD3) has a dose-dependent accumulation and a half-life of about 1.5 days^[2].
Otelixizumab targets the ε-chain of the CD3 T-lymphocyte surface receptor, which facilitates the activation of the autoreactive T-lymphocytes responsible for beta cell destruction^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Otelixizumab (ChAglyCD3) (100 μg/mouse; i.v.; once) results in durable disease remission dependent on transferable T cell–mediated tolerance in diabetic transgenic mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

916  [NCBI]

P07766

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.58 kDa

881191-44-2

Liquid

Colorless to light yellow

[Otelixizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda

• 
  Immobilized CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc, HY-P77610) can bind Otelixizumab. The EC₅₀ for this effect is 1.824 ng/mL.
• 
  Flow cytometric analysis of 10⁶ Jurkat cells with Otelixizumab (HY-P99211, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda1 (HY-P99992, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Kuhn C, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med. 2011 Feb 2;3(68):68ra10.  [Content Brief]

  [2]. Guglielmi C, et al. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. Expert Opin Biol Ther. 2016 Jun;16(6):841-6.  [Content Brief]